Replies to post #26319 on OncoSec Medical Inc (ONCSQ)

[jbem777]

It's an open label study, so expect interim results mid year. At the last conference Punit stated that since it was a multi center study, using the current standard of care, that enrollment would occur quickly and full results are expected at the end of 2015 or early 2016. If interim results are good, expect a buy out. Merck, BMY, or AZN can not let ONCS usurp the standard of care and I would expect a bidding war, as the combination could make pd1 alone, obsolete.

[furbush87]

Well we will know for sure once the trial is registered at clinicaltrial.gov, but I will venture some deductive reasoning. Most of the trials ONCS has done has been including 3 rounds of treatment, but only 1 round has actually been done. I suspect that the trial will be registered for a full year of treatment (that is what Keytruda has done in the past), but they should see results in 2-3 months, depending on how quickly patients register, I suspect that by mid may/june they should have some interim results. Now as to when they release that, well..... you tell me. This is one area Jbem and I strongly disagree, because I can't imagine a scenario that ONCS does a buyout or releases rights to immunoPulse right now.